ByteDance Spins Off AI Drug Discovery Unit Anew Labs, Raises $290M at $1.5B Valuation

ByteDance closed a $290 million funding round on September 17, 2026 for Anew Labs, its newly spun-off AI drug discovery unit, at a $1.5 billion valuation, with ByteDance retaining 56% of the business after the round.

A Deep Bench of Chinese and Global Investors

HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment headed the transaction alongside co-lead 5Y Capital, with participation from Gaorong Ventures, Primavera Venture Partners, Boyu Capital, the state-supported Shanghai Future Industries Fund, and SBP Group as a strategic investor — a syndicate spanning top-tier Chinese venture capital and state-backed investment.

Global Footprint From a Shanghai Base

Anew Labs is headquartered in Shanghai and also maintains offices in Singapore and San Francisco — a footprint that positions the company to operate across both Chinese and Western drug discovery and biotech investment ecosystems rather than remaining confined to a single regulatory or capital market.

What Anew Labs Actually Builds

The company develops AI systems for biomolecular structure prediction, molecular design, antibody design, and scientific reasoning for drug discovery. Its structure-prediction and protein-design models, including Protenix and PXDesign, have already produced real drug candidates, including an AI-designed IL-17 inhibitor — indicating the technology has moved from research demonstration toward actual candidate compounds.

Origins Inside ByteDance

Anew Labs traces its origins to an internal AI-for-Science team ByteDance formed back in 2021 — meaning this spinoff represents roughly five years of internal research maturing into an independently funded, majority-ByteDance-owned company rather than a from-scratch startup.

What This Means for AI-Driven Drug Discovery

A major consumer technology company spinning off a mature internal AI-for-science research effort into an independently funded $1.5 billion entity — while retaining majority ownership — is a specific signal that AI-driven drug discovery has moved well past experimental status inside large tech companies, with real drug candidates already in the pipeline rather than purely theoretical research output.